Long-Term Monitoring and Emergency Signs
At a Glance
For people with RRMS, MRI monitoring usually includes a new baseline scan about 3–6 months after starting treatment, a follow-up scan 6–12 months later, and ongoing scans based on stability. Sudden one-sided weakness, facial droop, speech trouble, seizures, or severe breathing or allergic symptoms require emergency care.
Living with RRMS means shifting from a “search for a diagnosis” to a “strategy of surveillance.” Because many changes in MS happen silently on an MRI before they cause physical symptoms, regular monitoring is your best tool for ensuring your treatment is working. This phase of care is about staying ahead of the disease while knowing exactly when to raise the alarm [1][2].
Your MRI Monitoring Schedule
Once you start a new Disease-Modifying Therapy (DMT), your doctor will use a series of “snapshots” to track its effectiveness. While every medication and clinic practice can vary, a typical surveillance framework often follows this pattern:
- The Re-Baseline Scan (e.g., 3–6 Months): This is perhaps the most important scan. It takes a few months for most DMTs to become fully effective. This scan establishes a new “baseline” of what your brain looks like while on the drug [1].
- The Follow-Up (e.g., 6–12 Months Later): A second scan is typically done 6 to 12 months after your re-baseline. Your doctor will compare these two scans to see if any new activity has occurred while the drug was at full strength [1].
- Maintenance: If your disease is stable, you may move to an annual MRI of the brain. Spinal cord surveillance or the use of contrast (gadolinium) is individualized and not universally required at every follow-up scan [1][3].
Addressing “Scan Anxiety”
It is perfectly normal to feel “scanxiety”—the mix of dread and nervousness that builds up before an MRI. Remember that a scan showing a new lesion is not a “failure” on your part; it is a vital piece of data that tells your team it may be time to adjust your strategy [4]. Communicating your anxiety to the technologist, using relaxation techniques, or arranging a prompt follow-up call to review results can help ease the psychological burden.
Distinguishing Fluctuations from Emergencies
Most day-to-day changes in how you feel—like a brief tingle in your fingers or a tired afternoon—are routine fluctuations. However, because you are taking medications that modify your immune system, there are specific situations that require medical attention.
When to Seek Emergency Care (Call 911 / Go to ER)
Go to the emergency room immediately if you experience sudden symptoms that could indicate a stroke or severe systemic reaction:
- Sudden weakness on one side of your body, facial droop, or inability to speak.
- Severe breathing difficulty or a seizure.
- Infusion Reactions: During or shortly after an infusion, seek immediate help for throat swelling, difficulty breathing, widespread hives, or feeling like you might faint [5].
When to Call Your Neurology Clinic Promptly
Contact your clinic directly (do not wait for your next appointment) if you experience:
- A “Different” Neurological Change: Any new symptom that is progressive, disabling, or feels completely different from your typical MS [6][7].
- Signs of PML: If you are on natalizumab or an S1P modulator (like fingolimod), be alert for progressive clumsiness, vision changes in both eyes, or cognitive “fog” that gets worse day by day. These can be early signs of Progressive Multifocal Leukoencephalopathy (PML), a rare but serious brain infection [8][9].
- Severe Infection: While on immunosuppressants, persistent productive coughs, painful urination, or unexplained systemic illness need prompt assessment. Note that some immunosuppressed people may not mount a high fever [10][11].
- The Risk of “Rebound”: If you must stop taking an S1P modulator (like fingolimod or siponimod), it is critical to do so only under strict medical supervision. Abruptly stopping these drugs can occasionally cause a “rebound” effect—a sudden, severe flare of MS activity 2 to 4 months after the last dose. Always follow your prescriber’s transition plan [12][13][7].
Summary: When to Wait vs. When to Act
- Routine: Symptoms that last minutes or hours and go away (like heat-related fatigue) [14].
- Prompt Clinic Call: A possible “true relapse”—new symptoms lasting more than 24 hours (like a new numb patch on your leg), or any concerning signs of infection [14].
- Emergency (Go to ER): Sudden confusion, inability to speak, facial droop, severe breathing difficulty, or severe allergic reactions [6][10].
Common questions in this guide
What MRI schedule is typical after I start an RRMS disease-modifying treatment?
Which symptoms mean I should call 911 or go to the emergency room?
When should I contact my neurology clinic about a new MS symptom?
What are the warning signs of PML in someone with RRMS?
Can stopping fingolimod or siponimod suddenly cause an MS rebound?
How can I tell a routine MS fluctuation from a possible relapse?
What can I do if MRI scans make me anxious?
One line in your results can change your plan.
A new MRI lesion may mean it is time to adjust the treatment strategy. We check your results against the latest research to help you prepare for what’s next.
Get notified when new evidence is published on relapsing-remitting multiple sclerosis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.
Arnold DL, Li D, Hohol M, et al.
Multiple sclerosis journal - experimental, translational and clinical 2015; (1()):2055217315589775 doi:10.1177/2055217315589775.
PMID: 28607695 - 2
NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.
Sormani MP, Muraro PA, Saccardi R, Mancardi G
Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(2)):201-204 doi:10.1177/1352458516645670.
PMID: 27207454 - 3
Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.
Wattjes MP, Rovira À, Miller D, et al.
Nature reviews. Neurology 2015; (11(10)):597-606 doi:10.1038/nrneurol.2015.157.
PMID: 26369511 - 4
Measuring treatment response to advance precision medicine for multiple sclerosis.
Calabresi PA, Kappos L, Giovannoni G, et al.
Annals of clinical and translational neurology 2021; (8(11)):2166-2173 doi:10.1002/acn3.51471.
PMID: 34704393 - 5
Post-infusion observation of patients with multiple sclerosis receiving natalizumab: Is it necessary?
Bafrani MA, Ahmadi NS, Idjadi FZ, et al.
Multiple sclerosis and related disorders 2026; (107()):106995 doi:10.1016/j.msard.2026.106995.
PMID: 41587505 - 6
Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.
Lo Buono V, D'Aleo G, Cammaroto S, et al.
Medicina (Kaunas, Lithuania) 2022; (58(4)) doi:10.3390/medicina58040551.
PMID: 35454389 - 7
Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?
Boudot de la Motte M, Louapre C, Bertrand A, et al.
Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(4)):614-616 doi:10.1177/1352458516682858.
PMID: 28273764 - 8
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.
Pavlovic D, Patera AC, Nyberg F, et al.
Therapeutic advances in neurological disorders 2015; (8(6)):255-73 doi:10.1177/1756285615602832.
PMID: 26600871 - 9
Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al.
JAMA neurology 2018; (75(7)):827-833 doi:10.1001/jamaneurol.2018.0094.
PMID: 29532061 - 10
Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.
Ong S, Kibbler J, Maxwell G, Steer J
BMJ case reports 2024; (17(1)) doi:10.1136/bcr-2023-255011.
PMID: 38171639 - 11
Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.
Smith TE, Kister I
Current neurology and neuroscience reports 2021; (21(7)):36 doi:10.1007/s11910-021-01117-y.
PMID: 34009478 - 12
Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal.
Koska V, Förster M, Brouzou K, et al.
Frontiers in neurology 2021; (12()):785180 doi:10.3389/fneur.2021.785180.
PMID: 34777236 - 13
Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.
Berger B, Baumgartner A, Rauer S, et al.
Journal of neuroimmunology 2015; (282()):118-22.
PMID: 25903738 - 14
Repository corticotropin injection in multiple sclerosis: an update.
Kutz CF, Dix AL
Neurodegenerative disease management 2018; (8(4)):217-225 doi:10.2217/nmt-2018-0008.
PMID: 29869572
This page explains long-term monitoring and warning signs in relapsing-remitting multiple sclerosis for informational purposes only and does not constitute medical advice. Contact your neurology team for individualized guidance, and call emergency services for severe or sudden symptoms.